CAV3 and cardiac hypertrophy: Caveolin-3 specifically inhibited the increased expression of ICav3.2 and suppressed the Ca2+-dependent hypertrophic calcineurin-NFAT (calcineurin/nuclear factor of activated T cell) signaling pathway under pathological cardiac hypertrophy condition, thus significantly decreased the peak ICav3.2 current density to improve cardiac function [53].